news

Researchers develop new immuno-oncology technique

A team has used viral gene editing and CRISPR to form a system that marks tumours for destruction, potentially improving immunotherapies.

A new system has been developed which prevents cancer cells from evading immune cells. The researchers say that their method could aid in eliminating tumours that immunotherapies may miss.

The study was conducted by researchers from Yale University, US. The process developed reduced melanoma and triple-negative breast and pancreatic cancer in mice, even those located far from the primary tumour source.

The researchers combined viral gene therapy and CRISPR gene-editing technology, into Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI). The researchers used a cell-based vaccination strategy to deliver the marker.

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

The process scans tens of thousands of cancer-related genes and then acts as a locator. MAEGI marks the tumour cells for immune destruction, which turns a cold tumour (lacking immune cells) into a hot tumour (with immune cells).

“And once those cells are identified, the immune system immediately recognises them if they show up in the future,” said Sidi Chen, assistant professor of genetics and senior author of the study.

The researchers used a cell-based vaccination strategy to deliver the marker”

In theory, the system should be effective against many cancer types, including those resistant to immunotherapy.

“This is an entirely new form of immunotherapy,” said Chen.

The study was published in Nature Immunology.

Related conditions

Related organisations

Related people

Leave a Reply

Your email address will not be published. Required fields are marked *